North America Legal Chronicle. November 12, 2024

EyePoint Pharmaceuticals, Inc.’s US$161 Million Public Offering Of Common Stock

By Marco Zingaro

Hogan Lovells advised EyePoint Pharmaceuticals on the offering. Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here